Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpop...

by APHINITY Steering Committee and Investigators, Bines, J., Caballero, C., Cameron, D., Cardoso, F., Clark, E., Cole, B.F, de Azambuja, E., Frank, E., Fumagalli, D., Gelber, R.D, Heeson, S., Kiermaier, A., Krop, I., Loi, S., Loibl, S., Piccart-Gebhart, M., Procter, M., Restuccia, E., Salgado, R., Tjan-Heijnen, V., Wang, X.V
Published 2022